Repatha

Repatha

evolocumab

Manufacturer:

Amgen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Evolocumab
Indications/Uses
Adjunct to diet & standard care therapy including moderate- to high-intensity statin therapy alone or in combination w/ other lipid-lowering therapy to reduce risk of MI, stroke & coronary revascularization in adults w/ atherosclerotic CV disease. Reduction of elevated LDL-C in adults w/ primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH): Adjunct to diet & statin therapy w/ or w/o other lipid-lowering therapies in patients requiring additional lowering of LDL-C, or alone or in combination w/ non-statin lipid-lowering therapies for patients whom statin is contraindicated. Adjunct to diet & other LDL-lowering therapies in patients w/ homozygous familial hypercholesterolemia (HoFH) requiring additional lowering of LDL-C.
Dosage/Direction for Use
SC Established CV disease or primary hyperlipidemia including HeFH 140 mg every 2 wk or 420 mg once mthly. HoFH 420 mg once mthly.
Contraindications
Special Precautions
Discontinue use if hypersensitivity reaction occurs. Severe hepatic impairment. Pregnancy & lactation. Ped patients <13 yr. Elderly.
Adverse Reactions
Nasopharyngitis, upper resp tract infection, influenza, back pain, inj site reactions (including erythema, pain, bruising), allergic reactions (rash, eczema, erythema, urticaria); DM, angioedema, influenza-like illness.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AX13 - evolocumab ; Belongs to the class of other lipid modifying agents.
Presentation/Packing
Form
Repatha soln for inj 140 mg/mL
Packing/Price
((auto-injector)) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in